Basic Information

Strain name
Common name
B-hVSIG4 mice
Catalog number

Targeting strategy

Gene targeting strategy for B-hVSIG4 mice. Coding sequences of human VSIG4 and mouse 3’UTR were inserted into exon 2 of mouse Vsig4 gene. Mouse Vsig4 gene was replaced with human VSIG4 gene.

mRNA expression analysis

Strain specific analysis of VSIG4 gene expression in wild-type C57BL/6 mice and homozygous B-hVSIG4 mice by RT-PCR. Mouse Vsig4 mRNA was detectable in liver tissue of wild-type C57BL/6 mice (+/+). Human VSIG4 mRNA was detectable only in homozygous B-hVSIG4 mice but not in wild-type mice.

In vivo efficacy of anti-human VSIG4 antibodies

Anti-tumor activity of anti-human VSIG4 antibody in humanized B-hVSIG4 mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hVSIG4 mice (female, 7-week-old, n=5). (A) Anti-human VSIG4 antibody (in house analog) inhibited MC38 tumor growth in B-hVSIG4 mice, (B) without negatively impacting body weight.


  1. Katschke, K.J., Jr., et al. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J Exp Med 204, 1319-1325 (2007).
  2. Lieberman, L.A., et al. Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. Clin Immunol 160, 286-291 (2015).
  3. Li, J., et al. VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism. Nat Commun 8, 1322 (2017).
  4. Liao, Y., et al. VSIG4 expression on macrophages facilitates lung cancer development. Lab Invest 94, 706-715 (2014).
  5. Xu, T., et al. VSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients. Am J Transl Res 7, 1172-1180 (2015).
  6. Trouw, L.A., Pickering, M.C. & Blom, A.M. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol 13, 538-547 (2017).
  7. He, J.Q., Wiesmann, C. & van Lookeren Campagne, M. A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol 45, 4041-4047 (2008).
  8. Small, A.G., et al., Complement receptor immunoglobulin: a control point in infection and immunity, inflammation and cancer. Swiss Med Wkly, 2016. 146: p. w14301.